Contemporary validation of cT1a vs. cT1b substaging of incidental prostate cancer-Reference-Cited by-同舟云学术

Contemporary validation of cT1a vs. cT1b substaging of incidental prostate cancer

Published:2024-04-28 Issue:1 Volume:42 Page:
ISSN:1433-8726
Container-title:World Journal of Urology
language:en
Short-container-title:World J Urol

Author:

Scheipner Lukas^ORCID,Baudo Andrea,Jannello Letizia Maria Ippolita,Siech Carolin,de Angelis Mario,Tian Zhe,Saad Fred,Shariat Shahrokh F.,Briganti Alberto,Chun Felix K. H.,Carmignani Luca,De Cobelli Ottavio,Mischinger Johannes,Ahyai Sascha,Karakiewicz Pierre I.

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1007/s00345-024-04940-3.pdf

Reference15 articles.

1. Amin MB, Greene FL, Edge SB, et al (2017) The Eighth Edition AJCC Cancer Staging Manual: Continuing to build a bridge from a population-based to a more “personalized” approach to cancer staging. CA Cancer J Clin 67:93–99. https://doi.org/10.3322/CAAC.21388

2. Capitanio U, Autorino R, Bandini M et al (2022) Incidental Prostate Cancer (cT1a–cT1b) is a relevant clinical and research entity and should be fully discussed in the international Prostate Cancer Guidelines. Eur Urol Oncol 5:256–258. https://doi.org/10.1016/j.euo.2021.03.005

3. Mottet N, Rouviere O, van der Kwast TH (2022) Incidental Prostate Cancer: a real need for expansion in Guidelines? Eur Urol Oncol 5:256–258. https://doi.org/10.1016/j.euo.2021.03.005

4. Andersson TML, Myklebust TÅ, Rutherford MJ et al (2021) The impact of excluding or including Death Certificate Initiated (DCI) cases on estimated cancer survival: a simulation study. Cancer Epidemiol 71:101881. https://doi.org/10.1016/J.CANEP.2020.101881

5. Cause of Death Recode - SEER Recodes. https://seer.cancer.gov/codrecode/. Accessed 12 Jun 2023